ChatPPG Editorial

Maternal Health Monitoring via PPG During Pregnancy: Preeclampsia, Fetal HR & Hemodynamic Assessment

**Pregnancy creates one of the most dynamic physiological states in human medicine, with profound cardiovascular adaptations that are both essential f...

ChatPPG Team
Published
8 min read
  • PPG & Signal Processing
Maternal Health Monitoring via PPG During Pregnancy: Preeclampsia, Fetal HR & Hemodynamic Assessment
Editorial illustration · Devices and signals are conceptual. Where shown, violet optical paths represent invisible infrared in false color.

Pregnancy creates one of the most dynamic physiological states in human medicine, with profound cardiovascular adaptations that are both essential for fetal development and responsible for the major complications that threaten maternal and fetal health. Photoplethysmography (PPG) is uniquely positioned to monitor these cardiovascular changes because it non-invasively captures information about blood volume, vascular tone, heart rate, and oxygen saturation in a continuous, wearable format that requires no ionizing radiation or invasive procedures. This article reviews the scientific evidence for PPG-based maternal health monitoring, covering preeclampsia screening, fetal heart rate detection, hemodynamic assessment, and the emerging role of wearable PPG in prenatal care.

For background on PPG signal generation and the physiological information encoded in the photoplethysmographic waveform, see our introduction to PPG technology.

Cardiovascular Adaptations in Pregnancy and Their PPG Signatures

Normal pregnancy involves dramatic cardiovascular remodeling that begins in the first trimester and peaks in the late second to early third trimester. Understanding these adaptations is essential for interpreting PPG signals in pregnant individuals.

Cardiac output increases by 30-50% through a combination of increased heart rate (10-20 BPM above baseline by the third trimester) and increased stroke volume (20-30% increase). Plasma volume expands by 40-50%, while red cell mass increases by only 20-30%, resulting in the physiological anemia of pregnancy (hemoglobin typically decreasing from 13-14 g/dL to 11-12 g/dL). Systemic vascular resistance decreases by 20-30% due to progesterone-mediated vasodilation and the low-resistance placental circulation. Mean arterial pressure decreases by 5-10 mmHg in mid-pregnancy before returning to pre-pregnancy levels near term (Sanghavi & Rutherford, 2014; doi:10.1161/CIRCULATIONAHA.114.009029).

Each of these changes produces measurable effects on the PPG waveform. The increased cardiac output and reduced vascular resistance result in higher pulse amplitude and a more pronounced dicrotic notch. The physiological anemia alters the ratio of oxy- to deoxyhemoglobin absorption, potentially affecting SpO2 calibration curves. The resting tachycardia is directly measurable from pulse rate. Most importantly, the vascular compliance changes alter the PPG waveform morphology in ways that reflect both normal adaptation and pathological processes like preeclampsia.

Preeclampsia Screening and Prediction

The Clinical Challenge

Preeclampsia affects 3-8% of pregnancies worldwide and remains a leading cause of maternal and perinatal morbidity and mortality. It is characterized by new-onset hypertension (systolic BP greater than 140 mmHg or diastolic BP greater than 90 mmHg) and proteinuria or other end-organ dysfunction after 20 weeks of gestation. The underlying pathophysiology involves abnormal placentation leading to placental ischemia, endothelial dysfunction, and systemic vascular inflammation.

Early prediction of preeclampsia allows targeted prophylaxis and intensified surveillance. Current first-trimester screening combines maternal risk factors, mean arterial pressure, uterine artery pulsatility index, and serum biomarkers (PAPP-A, PlGF) at 11-14 weeks. In the ASPRE trial, women identified as high risk by this screening who took aspirin 150 mg/day had preterm preeclampsia in 1.6% of cases versus 4.3% with placebo (odds ratio 0.38) (Rolnik et al., 2017; doi:10.1056/NEJMoa1704559).

PPG-Derived Vascular Indices for Preeclampsia

PPG waveform analysis can extract indices of arterial stiffness and vascular function that are altered in the pre-clinical phase of preeclampsia, weeks to months before hypertension develops. The two most studied indices are the stiffness index (SI) and the augmentation index (AIx).

The stiffness index is derived from the time delay between the systolic peak and the diastolic peak (or inflection point) of the PPG waveform. This delay corresponds to the round-trip transit time of the pulse wave from the measurement site to a major reflecting site and back, and is inversely related to pulse wave velocity and arterial stiffness. In normal pregnancy, SI decreases during the first and second trimesters as vasodilation reduces arterial stiffness, then increases toward term.

The augmentation index, which reflects the contribution of wave reflection to the systolic peak, is another marker of vascular function that can be estimated from PPG. Whether PPG-derived SI or AIx adds predictive value to established first-trimester screening has not yet been shown in large prospective cohorts.

Continuous Blood Pressure Monitoring

Given that hypertension is the defining feature of preeclampsia, continuous PPG-based blood pressure estimation has particular relevance in pregnancy monitoring. Pulse transit time (PTT) and pulse wave analysis methods can provide beat-to-beat BP estimates between clinic visits, potentially capturing transient hypertensive episodes missed by office measurements.

As outside pregnancy, PTT-based methods track relative changes within an individual better than absolute values and need periodic cuff recalibration. Pregnancy-specific validation is limited.

For more on continuous blood pressure estimation from PPG, see our coverage of cuffless blood pressure monitoring technology and the underlying algorithms.

Fetal Heart Rate Detection from PPG

The Technical Challenge

Non-invasive fetal heart rate (FHR) monitoring is a cornerstone of prenatal care, but current methods are either intermittent (Doppler auscultation during clinic visits) or require dedicated equipment (cardiotocography). The possibility of extracting fetal heart rate from maternal PPG signals has attracted significant research interest because it would enable continuous, wearable fetal monitoring without separate fetal-specific sensors.

The fundamental challenge is signal separation. The maternal cardiac signal dominates the PPG waveform by several orders of magnitude. The fetal cardiac pulsation, which must travel through the uterine wall, amniotic fluid, and maternal abdominal tissue to reach a surface sensor, produces a PPG modulation far weaker than the maternal signal. Extracting this signal requires sophisticated signal processing approaches.

Abdominal PPG Approaches

Proposed abdominal approaches place reflectance-mode PPG sensors on the maternal abdomen and use a maternal reference signal (for example, finger PPG) with adaptive noise cancellation, or multi-wavelength recordings with independent component analysis, to separate fetal from maternal components. These remain early feasibility work without large validation studies. The signal processing techniques used for maternal-fetal separation parallel those developed for motion artifact removal in PPG, with the maternal signal playing the role of the "artifact" in this context.

Wrist PPG for Fetal Heart Rate

A more speculative but clinically attractive approach is extracting fetal heart rate from the maternal wrist PPG, which would enable monitoring through a standard smartwatch. The fetal contribution to the peripheral pulse at the wrist is extremely small, making direct detection essentially impossible with current sensor technology. However, indirect detection through fetal-maternal heart rate coupling may be feasible.

Maternal Hemodynamic Assessment

Cardiac Output Estimation

Non-invasive cardiac output estimation during pregnancy is valuable for managing high-risk conditions including preeclampsia, peripartum cardiomyopathy, and valvular heart disease. PPG pulse contour analysis can provide beat-to-beat cardiac output estimates without the expense and complexity of echocardiography or thoracic bioimpedance.

Application to pregnancy requires recalibration, because the reduced vascular resistance and increased vascular compliance of pregnancy alter the relationship between pulse contour and cardiac output.

Peripheral Vascular Resistance Monitoring

Systemic vascular resistance (SVR) is a key hemodynamic parameter that decreases in normal pregnancy but fails to decrease or increases in preeclampsia. PPG waveform features that correlate with SVR include the reflection index (ratio of diastolic to systolic peak amplitudes), the b/a ratio of the second derivative waveform, and the dicrotic notch position.

If validated, PPG waveform analysis could serve as a low-cost screening tool in resource-limited settings where Doppler ultrasound is unavailable.

SpO2 Monitoring During Pregnancy

Oxygen saturation monitoring during pregnancy has specific clinical applications including assessment of respiratory compromise in severe preeclampsia/eclampsia, monitoring during magnesium sulfate administration, labor and delivery surveillance, and detection of peripartum pulmonary embolism.

Normal SpO2 values in pregnancy are typically 95-99%, similar to non-pregnant adults, though slight decreases (1-2%) may occur in the supine position during the third trimester due to diaphragmatic elevation and reduced functional residual capacity. In the supine position, aortocaval compression by the gravid uterus can reduce cardiac output and cause positional desaturation, which is detectable by continuous PPG monitoring and serves as a reminder to use left lateral positioning.

Obstructive sleep apnea is underdiagnosed in pregnancy, and wearable PPG-based SpO2 monitoring could help identify at-risk pregnancies that would benefit from formal sleep evaluation. See our blood oxygen level reference guide for context on SpO2 interpretation.

Wearable PPG for Continuous Prenatal Monitoring

Current Evidence from Consumer Devices

The proliferation of PPG-enabled consumer wearables has created opportunities for passive, continuous maternal health monitoring. Several research groups have explored using commercial smartwatches and fitness trackers for pregnancy surveillance. Longitudinal wearable data can capture the expected rise in resting heart rate across gestation, but whether these trajectories predict complications has not been established in large validated cohorts.

Challenges and Limitations

Despite promising results, several challenges limit the clinical deployment of wearable PPG for pregnancy monitoring. Gestational edema, particularly in the third trimester, alters tissue optical properties and can degrade PPG signal quality. Weight gain and fluid redistribution may affect sensor fit and contact pressure. The gestational hemoglobin decrease alters the optical absorption profile used for SpO2 calibration. Skin pigmentation effects on PPG accuracy, already a known issue in non-pregnant populations, may be amplified by pregnancy-related changes in melanin distribution and skin perfusion.

Most critically, the algorithms embedded in consumer devices are validated on general adult populations, not pregnant individuals. Pregnancy-specific calibration and validation studies are needed before clinical decision-making can rely on these measurements. The signal processing challenges of adapting existing PPG algorithms for pregnancy-specific physiology represent an active area of research.

Future Directions

AI-Driven Risk Stratification

Machine learning models that integrate continuous PPG features (heart rate trends, HRV dynamics, vascular indices, SpO2 patterns) with clinical data (maternal age, BMI, medical history, biomarkers) could enable personalized pregnancy risk assessment.

Point-of-Care Hemoglobin Monitoring

Non-invasive hemoglobin estimation from multi-wavelength PPG could reduce the need for frequent venipuncture during pregnancy, where hemoglobin is routinely monitored. Current accuracy is not yet sufficient to replace laboratory testing for transfusion decisions.

Remote Monitoring and Telehealth Integration

The COVID-19 pandemic accelerated adoption of remote prenatal care models, and wearable PPG monitoring fits naturally into telehealth frameworks. Continuous PPG data streamed from home-based wearables to clinical dashboards could enable remote surveillance of high-risk pregnancies, reducing unnecessary clinic visits while maintaining safety. Integration with existing telehealth platforms and electronic health records is a technical challenge that requires standardized data formats and clinical decision support algorithms validated for obstetric applications.

Conclusion

PPG technology offers a compelling platform for maternal health monitoring during pregnancy, with proposed applications ranging from preeclampsia screening through vascular indices, to fetal heart rate detection via advanced signal processing, to continuous hemodynamic assessment through waveform analysis. Most of these remain research-stage and need pregnancy-specific validation. The non-invasive, wearable nature of PPG sensors makes them inherently suitable for longitudinal pregnancy monitoring, where frequent assessment of cardiovascular parameters is clinically important but current methods are episodic and resource-intensive. As PPG algorithms are refined for pregnancy-specific physiology and validation studies expand to diverse populations, PPG-based prenatal monitoring has the potential to improve outcomes for the estimated 140 million pregnancies that occur worldwide each year.

References

  • Rolnik, D. L., Wright, D., Poon, L. C., O'Gorman, N., Syngelaki, A., de Paco Matallana, C., et al. (2017). Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine, 377(7), 613-622. https://doi.org/10.1056/NEJMoa1704559
  • Sanghavi, M., & Rutherford, J. D. (2014). Cardiovascular physiology of pregnancy. Circulation, 130(12), 1003-1008. https://doi.org/10.1161/CIRCULATIONAHA.114.009029

Related articles